Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Allison Watson
Genetic screening provides actionable findings in one in six people
Genetic screening provides actionable findings in one in six people 31 August 2021 Appeared in BioNews 1110 Offering healthy people genetic screening could provide clinically important information in over 15 percent of cases. Researchers from the USA, Canada and Singapore offered proactive screening to adult participants through local primary and specialist healthcare facilities.
Genetic testing advances revealed at European Human Genetics Conference
Genetic testing advances revealed at European Human Genetics Conference 31 August 2021 Appeared in BioNews 1110 Genetic testing could prove useful for determining a diagnosis and prognosis for people with epilepsy, attendees at the European Human Genetics Conference heard. Originally due to take place in Vienna, the conference hosted by the European Society of Human Genetics took place online due to COVID-19 restrictions between 28 and 30 August 2021.
Dr Beverly Searle, CEO of charity Unique, to retire
Dr Beverly Searle, CEO of charity Unique, to retire 23 August 2021 Appeared in BioNews 1109 Dr Beverly Searle, CEO of Unique, is retiring at the end of August, marking the end of more than 30 years of service to the charity for people with rare chromosomal conditions.
Nationwide UK public dialogue supports whole genome sequencing in newborns
Nationwide UK public dialogue supports whole genome sequencing in newborns 12 July 2021 Appeared in BioNews 1103 Members of the UK public are largely supportive of the use of whole genome sequencing (WGS) in newborn screening, according to a national public dialogue. Currently, newborns are tested at day five, via heel prick or 'blood spot' tests, for nine serious, but treatable, genetic conditions include cystic fibrosis, sickle cell disease and certain metabolic disorders.
FILM: Sandy Starr and Simon Wilde discuss whole genome sequencing, newborn screening and public dialogue
FILM: Sandy Starr and Simon Wilde discuss whole genome sequencing, newborn screening and public dialogue 9 July 2021 Appeared in BioNews 1103 This film documents a conversation between Sandy Starr (deputy director of the Progress Educational Trust) and Simon Wilde (engagement director at Genomics England) about a new report on whole genome sequencing and newborn screening. (If you cannot see the film below, click here to view it.) The main themes of the conversation are as follows.
A matter of diagnosis... and why diagnosis matters
A matter of diagnosis... and why diagnosis matters 28 June 2021 By Allison Watson CEO at Ring20 Research and Support UK, CIO and European patient advocate co-lead for the European Reference Network for rare and complex epilepsies, and mum to David with r(20) syndrome Appeared in BioNews 1101 Ring chromosome 20 syndrome [r(20) syndrome] is an ultra-rare, difficult to treat epilepsy, often accompanied by intellectual disability and behaviour disorder.
Five new truths about zero-based budgeting
Five new myths and realities illustrate how the potential of zero-based budgeting has grown. What could zero do for you? In “Five myths (and realities) about zero-based budgeting,” we described just how powerful zero could be in an environment where, every year, budgets start from zero rather than an increase or decrease compared to the previous year.
Microsoft’s acquisition of Cloudyn will help Azure customers manage and optimize their cloud usage - The Official Microsoft Blog
I am pleased to announce that Microsoft has signed a definitive agreement to acquire Cloudyn, an innovative company that helps enterprises and managed service providers optimize their investments in cloud services. As customers grow their cloud usage across many projects, it can be challenging to gain visibility and understand costs for existing projects, to optimize those investments and to project future usage.
What does automation mean for G&A and the back office?
A lot. By incorporating available technologies, redeploying employees, and reimagining processes, companies can dramatically increase performance and greatly reduce costs. The performance of general and administrative (G&A) functions varies dramatically among companies, and the differential is poised to widen. As new forms of automation—fueled by advances in areas such as robotics and artificial intelligence—transform the world of work, G&A functions will be transformed, too.
What does automation mean for G&A and the back office?
A lot. By incorporating available technologies, redeploying employees and reimagining processes, companies can dramatically increase performance and greatly reduce costs. The performance of general and administrative (G&A) functions varies dramatically among companies, and the differential is poised to widen. As new forms of automation—fueled by advances in areas such as robotics and artificial intelligence—transform the world of work, G&A functions will be transformed, too.
The truth about zero-based budgeting: ZBB for consumer-goods players
Ten myths and realities illustrate the power and practicalities of zero-based budgeting for the consumer-packaged-goods industry. In industry after industry, zero-based budgeting (ZBB) is capturing the imagination of investors, analysts, boards of directors, and corporate executives as the methodology gains traction—and continues to deliver results.
Who should pay for support functions?
Traditional allocation of support-function costs isn’t working well, executives say. They need a better way to foster value-conscious decisions without creating too much complexity. Throughout the world, organizations in virtually every sector have revolutionized how they manage their support functions. New technologies, partnerships, and sources of talent are turning areas once viewed only as cost centers into new generators of competitive advantage.
Can you achieve and sustain G&A cost reductions?
Yes, but not by playing it safe. Set big goals, insist on a cultural shift, and model from the top. The companies that currently make up the S&P Global 1200 index spend an estimated $1.8 trillion annually in aggregate general and administrative (G&A) expenses. Likely, many corporate leaders believe their organizations can do at least a little better in keeping G&A expenses under control.
Você consegue alcançar e manter uma redução dos custos administrativos?
Sim, mas não será fácil. Defina metas ousadas, insista em uma mudança cultural e crie um modelo a partir do topo. The companies that currently make up the S&P Global 1200 index spend an estimated $1.8 trillion annually in aggregate general and administrative (G&A) expenses. Likely, many corporate leaders believe their organizations can do at least a little better in keeping G&A expenses under control.
Can you achieve and sustain G&A cost reductions?
Yes, but not by playing it safe. Set big goals, insist on a cultural shift, and model from the top. The companies that currently make up the S&P Global 1200 index spend an estimated $1.8 trillion annually in aggregate general and administrative (G&A) expenses. Likely, many corporate leaders believe their organizations can do at least a little better in keeping G&A expenses under control.
Maximizing the value of G&A
Reductions in general and administrative expenses flow right to the bottom line, but slash the wrong areas and you’ll get burned. We suggest a more strategic approach. If there has ever been an earnings presentation where a CEO was asked why general and administrative (G&A) expenses were too low, we have yet to see it.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Allison
Contact Allison, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack